Oramed Pharmaceuticals Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC.(Exact Name of Registrant as Specified in Its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). As of May 19, 2026, there were 40,926,081 shares of the issuer’s common stock, $0.012 par value per share, outstanding. ORAMED PHARMACEUTICALS INC.FORM 10-Q TABLE OF CONTENTS PART I - FINANCIAL INFORMATION1ITEM 1 - FINANCIAL STATEMENTS1ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS33ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK43ITEM 4 - CONTROLS AND PROCEDURES43PART II - OTHER INFORMATION44ITEM 1 - LEGAL PROCEEDINGS44ITEM 1A - RISK FACTORS44ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS44ITEM 3 - DEFAULTS UPON SENIOR SECURITIES44ITEM 4 - MINE SAFETY DISCLOSURES44ITEM 5 - OTHER INFORMATION45ITEM 6 - EXHIBITS46 Cautionary Statement Regarding Forward-Looking Statements The statements contained in this Quarterly Report on Form 10-Q that are not historical facts are “forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws and the Israeli securitieslaw. Words such as “expects,” “anticipates,” “intends,” “plans,” “planned expenditures,” “believes,” “seeks,” “estimates,” “considers”and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed torepresent an all-inclusive means of identifying forward-looking statements as denoted in this Quarterly Report on Form 10-Q.Additionally, statements concerning future matters are forward-looking statements. We remind readers that forward-looking statementsare merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks thatcould cause the actual results, performance, levels of activity, or our achievements, or industry results, to be materially different fromany future results, performance, levels of activity, or our achievements, or industry results, expressed or implied by such forward-looking statements. Such forward-looking statements include, among other statements, statements regarding the following: ●our plan to evaluate potential strategic opportunities;●our potential repurchases of shares of our common stock;●our ability to recover the proceeds and/or collateral under the Tranche A Note and Tranche B Note(as defined herein) andrelated agreements from Scilex Holding Company, or Scilex;●the fluctuating market price and liquidity of the common stock of Scilex, Alpha Tau and Lifeward underlying thewarrants we hold;●our loan agreements in real estate projects, including, but not limited to, agreements to finance a real estate project, orProfit Sharing Loan Agreement, expose us to potential market, liquidity, and execution risks;●our various real estate investments involve significant risks and might not provide long-term value appreciation andpotential income streams that we expect to receive;●our exposure to potential litigation;●our ability to enhance value for our stockholders;●the expected benefits, risks and impact of the Lifeward transactions, including the transfer of our POD™ technologyplatform to OraTech Pharmaceuticals Ltd., and our ability to recover the value of our investment in Lifeward, includingthrough